LTK is a paralog of anaplastic lymphoma kinase ALK [15], and is only expressed in myeloma cells following the rare event of an ALK-translocation; hence, ALK-inhibitors have not generally been used in myeloma therapies [16]. This evidence concerns the gene ALK and plasma cell myeloma.